Clinical Trials Logo

Clinical Trial Summary

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking at several other research questions, including: - What side effects may happen from taking the study drugs - How much study drug is in your blood at different times - Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects) - How administering the study drugs might improve your quality of life


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05785767
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email clinicaltrials@regeneron.com
Status Recruiting
Phase Phase 2/Phase 3
Start date June 30, 2023
Completion date February 5, 2032

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04263051 - Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer Phase 2
Recruiting NCT05489731 - VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer Phase 1
Completed NCT01240447 - Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients Phase 2
Completed NCT00737867 - Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer Phase 3
Recruiting NCT05504278 - Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation Phase 1
Recruiting NCT05482568 - A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT06043973 - Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance Phase 3
Completed NCT00948675 - Study of Participants With Advanced Non-Small Cell Lung Cancer Phase 3
Active, not recruiting NCT03681483 - RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer Phase 1
Terminated NCT05001724 - KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent Phase 2/Phase 3
Recruiting NCT05099172 - First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) Phase 1/Phase 2
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT00874328 - A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Completed NCT00487669 - Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT03516981 - A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) Phase 2
Recruiting NCT03334864 - Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
Terminated NCT00783471 - Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) Phase 2
Completed NCT00330746 - CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer Phase 2
Completed NCT03117335 - Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer Phase 3
Terminated NCT00345059 - The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer Phase 3